Abstract
RSV and seasonal influenza are two of the most important causes of respiratory infection that consistently peak during winter months in the U.S. Here, we characterized the circulation of these viruses in the U.S. with weekly positive case reports and genetic surveillance and used a mathematical modeling approach to explore their potential interaction at an HHS regional level. Our analyses showed RSV and seasonal influenza co-circulate with various relatively epidemic sizes and seasonal overlaps across seasons and regions. We found RSV might have different evolutionary dynamics compared to seasonal influenza, with local persistence may play a role in underlying annual epidemics. Our analysis supports a competitive interaction between RSV and seasonal influenza in most HHS regions and we speculate that cross-immunity after infection might be the major driver of viral competition. Together, our work supports the competition between RSV and seasonal influenza across the U.S. at a population level. Our findings are important for the future development of protective strategies against these respiratory viruses.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute of Allergy and Infectious Diseases, a component of the NIH, Department of Health and Human Services, under contract 75N93019C00052 (J.C. and J.B.) and Contract No. 75N93021C00018 (NIAID Centers of Excellence for Influenza Research and Response, CEIRR) (J.B. and P.R.). J.B. and P.R. are funded in part from the Centers for Disease Control under Contract No. 75D30119C06826 and 75D30121C11990 and NU50CK000626. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally located at NCBI GenBank and GISAID
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
